Premium
Taux plasmatiques de lidocaine et de prilocaine après application d’Oraqix ® , un nouvel anesthésique intra poche, chez des patients atteints de parodontites avancées
Author(s) -
Friskopp Johan,
Huledal Gunilla
Publication year - 2001
Publication title -
journal of clinical periodontology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.456
H-Index - 151
eISSN - 1600-051X
pISSN - 0303-6979
DOI - 10.1034/j.1600-051x.2001.028005425.x
Subject(s) - prilocaine , lidocaine , medicine , local anesthetic , anesthesia , gingival margin , periodontitis , anesthetic , dentistry
Background, aims: Oraqix ® , a new non‐injection local anesthetic, lidocaine/prilocaine gel 5%, has been developed to provide pain relief in association with periodontal probing and scaling/root planing (SRP). The aim of this open study was to describe the plasma profiles of lidocaine and prilocaine following a single dose of Oraqix ® to patients with advanced periodontitis. Methods: 10 patients with 18 to 28 teeth with pocket depths of at least 4 mm were included. Oraqix ® was applied in the pockets around all the teeth in the mouth by means of a blunt applicator. The total dose applied per patient was 0.9 to 3.5 g. Directly thereafter all the pockets were probed and 3 teeth subjected to SRP. The mouth was rinsed out with a glass of water 20–27 min after the application of the gel. Blood samples were collected before and up to 90 min after the start of application of Oraqix ® . Results: Peak plasma concentrations of lidocaine (99–266 ng/ml) and prilocaine (46–118 ng/ml) occurred 20–40 min after the start of application. These levels were low compared to those reported to cause initial signs of CNS toxicity (5000–6000 ng/ml). Side‐effects were few and mild local effects of short duration. Discussion: In conclusion, there is a large safety margin with respect to systemic effects following the application of up to 3.5 g Oraqix ® in periodontal pockets.